JRCT ID: jRCT2031230424
Registered date:24/10/2023
A phase III, randomized, active-comparator, observer-blind, non-inferiority study to demonstrate the immunogenicity and safety of DS-5670d(monovalent: omicron XBB.1.5) in adults and children aged 12 years and older
Basic Information
Recruitment status | Not Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Prevention of infection due to SARS-CoV-2 |
Date of first enrollment | 09/01/2024 |
Target sample size | 690 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | A dose of either DS-5670d (0.6 mL) or Comirnaty RTU IM (0.3 mL) will be intramuscularly administered to the deltoid muscle of the upper arm. |
Outcome(s)
Primary Outcome | - The GMT of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in adults and children aged 12 years and older with at least one of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history. - The seroresponse rate of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in adults and children aged 12 years and older with at least one of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history. |
---|---|
Secondary Outcome | - The GMT of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in adults and children aged 12 years and older regardless of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history. - The seroresponse rate of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in adults and children aged 12 years and older regardless of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history. |
Key inclusion & exclusion criteria
Age minimum | >= 12age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | 1) Subjects aged 12 years and older at the time of informed consent. 2) Having provided written consent to study participation. 3) Able to comply with the rules of the study, record symptoms via electronic diary by himself/herself or his/her legal representative, undergo physical examinations and tests that are specified in the protocol, and report symptoms or other issues (report from his/her legal representative to be available). |
Exclude criteria | 1) Having any serious cardiovascular, renal, hepatic, blood, neuropsychiatric, developmental disorder, thrombocytopenia, or coagulopathy. 2) Having a medical history of vaccination-related convulsions or epilepsy. 3) Having a concurrent or medical history of myocarditis or pericarditis. 4) Having tested positive within 3 months before informed consent for SARS-CoV-2 infection (based on RT-PCR, other nucleic acid detection methods, or SARS-CoV-2 antigen test), or having been diagnosed with COVID-19 based on a physician's examination. 5) Having been diagnosed with immunodeficiency in the past or having a close relative with congenital immunodeficiency. 6) Having symptoms suspected of SARS-CoV-2 infection (eg, respiratory symptoms, headache, malaise, anosmia, dysgeusia, pharyngeal pain) at the time of informed consent. 7) Having tested positive for SARS-CoV-2 antigen test at the time of eligibility evaluation. 8) Having tested positive for SARS-CoV-2 antibody test at the time of eligibility evaluation, with symptoms suspected ofSARS-CoV-2 infection (eg, respiratory symptoms, headache, malaise, anosmia, dysgeusia, pharyngeal pain) within 3 months before informed consent. |
Related Information
Primary Sponsor | Inoguchi Akihiro |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Ministry of Health, Labour and Welfare |
Secondary ID(s) |
Contact
Public contact | |
Name | Contact for Clinical Trial Information |
Address | 1-2-58, Hiromachi, Shinagawa-ku, Tokyo Tokyo Japan 140-8710 |
Telephone | +81-3-6225-1111 |
dsclinicaltrial@daiichisankyo.co.jp | |
Affiliation | Daiichi Sankyo Co., Ltd. |
Scientific contact | |
Name | Akihiro Inoguchi |
Address | 1-2-58, Hiromachi, Shinagawa-ku, Tokyo Tokyo Japan 140-8710 |
Telephone | +81-3-6225-1111 |
dsclinicaltrial@daiichisankyo.co.jp | |
Affiliation | Daiichi Sankyo Co., Ltd. |